Boston Scientific CorporationNYSE: BSX
Health Care · Health Care Equipment
$45.17
+0.49%
Vol: 11.4M
Research Digest
Thursday, June 18, 2026
Boston Scientific shares fell another 4.2% to a 52-week low on June 17 as analysts kept cutting targets on slowing electrophysiology and Watchman growth.
Boston Scientific (BSX) dropped 4.2% to $44.95 on June 17, 2026, extending a slide that has wiped out roughly 53% of the stock year-to-date and pushed it to fresh 52-week lows. The decline follows a 2026 organic revenue growth guidance cut from 10%-11% to 6.5%-8%, which spooked investors over deceleration in its electrophysiology and Watchman franchises and possible share loss to Medtronic. A wave of analyst downgrades and target cuts has followed: Wells Fargo's Lawrence Biegelsen cut to Equal Weight from Overweight with a $55 target (down from $75), Daiwa moved to Neutral, and others including Canaccord ($71), Needham ($77) and Wells Fargo ($75) lowered targets. Heavy put volume and multiple securities class-action filings have added to negative sentiment. The bear case is that growth deceleration is structural rather than transitory, with continued competitive pressure and litigation overhang capping any near-term rebound. Q2 EPS is projected at $0.83 on revenue of about $5.39 billion, so the next print will be a key test of whether the guidance reset was conservative enough.
Previous Market Intelligence
13 daysJun 17No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 16No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 15Boston Scientific shares hit a 52-week low and are down roughly 50% year-to-date as the company walks back its full-year 2026 guidance amid a slowdown in its Watchman and electrophysiology franchises and a Wells Fargo downgrade.Negative▶
Boston Scientific stock traded around $46-48 on June 15, near a 52-week low, with shares down approximately 50% year-to-date as the medtech firm continues to walk back its full-year 2026 guidance. Wells Fargo downgraded the stock, citing a slowdown in the high-margin Watchman left atrial appendage closure franchise and softening electrophysiology sales amid rising competition. The deterioration follows Q1 2026 net sales of $5.203 billion (up 11.6% reported, 9.4% operational), underscoring how sharply sentiment has shifted on forward growth. To support the shares, the company entered a $2 billion accelerated share repurchase agreement with JPMorgan Chase. The bear case is intensifying: beyond the guidance cuts and competitive pressure on Watchman, the company faces investor securities class-action lawsuits and class-action deadlines tied to alleged securities fraud, adding legal overhang to an already weakening growth narrative.
Jun 14No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 21Boston Scientific announced a $2 billion accelerated share repurchase with JPMorgan on May 18, plus a $1.5B strategic investment for 34% stake in MiRus.Mixed▶
Boston Scientific entered into a $2 billion accelerated share repurchase agreement with JPMorgan Chase on May 18 as part of its $5B authorization, with the initial tranche representing roughly 30.4M shares based on the May 15 closing price of $52.68. The company also announced a $1.5 billion strategic investment to acquire a 34% stake in privately held MiRus with an option for full acquisition subject to clinical milestones. Shares climbed about 5-6% on the news after recently hitting a 52-week low of $53.10. However, Bank of America lowered its price target to $68 from $105 while maintaining a Buy rating. The stock has declined 12% over the past 30 days on concerns about WATCHMAN and U.S. electrophysiology growth, and management previously cut 2026 organic growth guidance to 6.5%-8.0%.
May 20Boston Scientific entered a $2 billion accelerated share repurchase agreement with JPMorgan on May 18, 2026, lifting shares about 6.2% as the company executes its $5B buyback authorization.Mixed▶
On May 18, 2026, Boston Scientific announced a $2 billion accelerated share repurchase (ASR) agreement with JPMorgan Chase, retiring roughly 30.4 million shares initially based on the May 15 closing price of $52.68. The buyback is expected to add about $0.02 to adjusted EPS for full-year 2026. The company also reportedly committed to a $1.5 billion investment for a 34% stake in MiRus with an option for full acquisition. BSX shares had previously declined about 12% over the prior 30 days on concerns about slowing growth in WATCHMAN and electrophysiology, with management cutting its 2026 organic growth guidance to 6.5%-8.0%. Bank of America trimmed its price target to $68 from $105 while keeping a Buy, though the broader analyst consensus remains Strong Buy with an average target near $83. Investors are weighing the capital return signal against near-term segment softness.
May 19Boston Scientific announced a $2 billion accelerated share repurchase with JPMorgan and a $1.5 billion investment for ~34% stake in MiRus LLC, while Bank of America cut its price target to $68 from $105 amid medtech valuation reset.Mixed▶
On May 18, 2026, Boston Scientific entered into a $2 billion accelerated share repurchase agreement with JPMorgan Chase as part of its previously announced $5 billion authorization, expected to add about $0.02 to adjusted FY26 EPS. The company also invested $1.5 billion for roughly a 34% equity stake in privately held MiRus LLC, securing an exclusive option to acquire its balloon-expandable TAVR system subject to milestones. Shares rose ~5% Monday on the news. However, Bank of America slashed its price target to $68 from $105 (maintaining Buy), citing a changing medtech valuation environment. BSX is down nearly 43% year-to-date amid concerns over WATCHMAN, U.S. electrophysiology, and urology pressures, with management calling Q2 the likely trough. The bear case: heavy capital deployment into MiRus carries execution risk on a still-uncleared TAVR product, and consecutive guidance resets and a pending securities class action (May 4 lead plaintiff deadline) keep sentiment fragile.
May 18Boston Scientific launched a $2 billion accelerated share repurchase, accretive ~$0.02 to 2026 adjusted EPSPositive▶
On May 18, 2026 Boston Scientific entered into a $2 billion accelerated share repurchase (ASR) agreement with JPMorgan Chase Bank, part of its previously announced $5 billion repurchase authorization. The company will initially receive shares with aggregate value of 80% of the repurchase price based on the May 15 closing price, equating to approximately 30.4 million shares, with an expected $0.02 accretion to 2026 adjusted EPS on top of April 22 guidance. BSX traded between $52.52-$54.40 on May 18 around $52.75, with earlier May weakness tied to lowered full-year organic growth guidance of 6.5-8% and integration risk from the announced $14.5B Penumbra acquisition. Q1 2026 organic sales grew 9.4% and adjusted EPS rose 6%, but EP, WATCHMAN, and Urology headwinds led to the guidance cut. On May 7 the FDA flagged a software upgrade for specific BSX pacemakers tied to a recall. Boston Scientific will present at Bernstein's Strategic Decisions Conference on May 27. 22-analyst consensus is Strong Buy with a $93.18 price target.
May 15FDA issued Class I recall on Boston Scientific Accolade pacemakers May 8 over software-related battery issue causing devices to enter Safety Mode.Negative▶
The FDA issued a Class I recall (most serious) on May 8 for certain Boston Scientific Accolade pacemakers and cardiac resynchronization therapy pacemakers due to a software-related battery issue that could cause devices to enter Safety Mode and limit pacing functionality. Boston Scientific also announced the first patient treated with its Seismiq IVL system in the ELEGANCE registry on May 13. The company is digesting its $14.5B Penumbra acquisition announcement and lowered full-year sales growth guidance to 6.5-8% (from 10.5-11.5%) and adjusted EPS to $3.34-$3.41 (from $3.43-$3.49), citing electrophysiology and Watchman franchise challenges. Stock hit a 52-week low of $53.10 in May and trades around $53.61 despite a $93.18 average PT among 22 analysts (Strong Buy).
May 14Boston Scientific hit a 52-week low near $53 after cutting 2026 guidance and facing rising competition in electrophysiology and WatchmanNegative▶
Boston Scientific shares slid to a 52-week low of $53.10 in mid-May 2026, with the stock trading between $52.81 and $54.25 on May 13. The company cut full-year 2026 sales growth guidance to 7-8.5% from 10.5-11.5% and lowered adjusted EPS guidance to $3.34-$3.41 from $3.43-$3.49. CEO Mike Mahoney attributed the downgrade to challenges in electrophysiology and the Watchman franchise, with rising competition in atrial fibrillation treatments and a $14.5B Penumbra acquisition under scrutiny. Multiple firms cut price targets in late April including RBC, Oppenheimer, Needham, Canaccord, Truist, Baird, and Wells Fargo, while Nephron Research upgraded to Buy. Boston Scientific filed a $565.7M shelf registration for up to 10M ESOP-related shares, and shareholders approved charter amendments eliminating supermajority voting. The company will present at Bernstein's Strategic Decisions Conference on May 27.
May 13Boston Scientific opens around $54 as Penumbra shareholders approve the $14.5B acquisition while 2026 growth guidance is cut.Negative▶
On May 11 Boston Scientific shares opened at $53.89 after Penumbra shareholders approved the $14.5B merger, expanding BSX into neurovascular markets but adding debt and integration risk. Management cut 2026 organic growth guidance to 6.5-8.5% (from 10.5-11.5%) and adjusted EPS guidance to $3.34-$3.41, citing softness in electrophysiology and the Watchman franchise (Q1 Watchman sales of $506M, +19.2% YoY, below internal expectations); urology grew just ~2%. Neuromodulation remained a bright spot at +15% YoY. Polen Capital sold its stake on competitive pressure.
May 12FDA issues Class I recall on Boston Scientific ACCOLADE pacemakers May 8 over software-related battery issue.Mixed▶
The FDA issued a Class I recall correction on May 8 for certain Boston Scientific ACCOLADE pacemakers and cardiac resynchronization therapy pacemakers after a software-related battery issue could push affected devices into Safety Mode and limit pacing functionality. The correction does not require device removal but mandates clinician software upgrades. Shares hit a fresh 52-week low of $55.94 on May 5 amid analyst downgrades and softer guidance, and trade near $53.39 on May 12. The company will participate in Bernstein's 42nd Annual Strategic Decisions Conference on May 27 with CEO Mike Mahoney. At HRS 2026, BSX presented FARAFLEX PFA ELEVATE-PF data showing 95.6% PVI durability at two months, and a new coronary IVL system performed well in a first-in-human study.
May 11FDA issued a Class I recall correction for Boston Scientific ACCOLADE pacemakers due to a software-related battery issue, while shares hit a 52-week low of $55.94.Negative▶
On May 8, 2026, the FDA issued its most serious (Class I) recall correction for certain Boston Scientific ACCOLADE pacemakers and CRT pacemakers after identifying a software-related battery issue that could cause devices to enter Safety Mode and limit pacing. The correction does not require device removal but mandates a software upgrade to reduce premature battery depletion risk. Shares hit a fresh 52-week low of $55.94 on May 5 amid analyst downgrades and slashed 2026 guidance, reportedly down 45.2% over the past year. The company also withdrew full-year 2026 guidance pending its acquisition of Penumbra. Risk: ongoing recall liability and weakened sentiment could pressure shares further despite positive FARAPULSE/WATCHMAN trial data.
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| ABTABBOTT | $88.54 | +0.05% | -0.4% | 14.6x | 0.62 | $154.2B |
| ISRGINTUITIVE | $403.75 | +0.39% | -8.9% | 34.1x | 1.45 | $142.4B |
| SYKSTRYKER | $309.97 | +2.93% | -5.2% | 18.0x | 0.79 | $115.4B |
| MDTMEDTRONIC | $78.88 | +0.95% | -0.6% | 12.2x | 0.60 | $100.3B |
| BSXBOSTON | $45.17 | +0.49% | -20.9% | 12.1x | 0.56 | $66.8B |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price below 200d MA — bearish structure.